An observational study in Acute Myocardial Infarction and Coronary Artery Disease, sponsored by Clinical Centre of Serbia. Status unknown at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-29.
Sponsored by Clinical Centre of Serbia · Observational
Randomized studies may often be burdened by the selective nature of patient inclusion thus not reflecting real-world outcomes. This is evident from the discrepancy in the mortality rates reported in major randomized trials enrolling patients with acute myocardial infarction (AMI), as compared with registry data.
The primary objective of this observational study is to assess short- and long-term outcomes of unselected, real-world patients presenting with AMI and treated with contemporary percutaneous coronary intervention (PCI).
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Clinical Centre of Serbia is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This registry is based on consecutive patients with the initial diagnosis of acute myocardial infarction on admission to hospital, who are referred to invasive treatment, i.e. invasive coronary angiography with an intention to perform percutaneous coronary intervention. The study population will include both retrospective, multi-center registry data starting with the year 2009, and the prospectively enrolled patients according to the same pre-specified, broad inclusion/exclusion criteria. The underlying intention is to short- and long-term outcomes of a large population of unselected, real-world patients presenting with AMI and treated with PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Consecutive patients with acute myocardial infarction
Procedure: Percutaneous Coronary Intervention
Percutaneous Coronary Intervention
Rate of all-cause mortality
Rate of all-cause mortality at 1 year
Time frame: 1 year
Rate of all-cause mortality
Rate of all-cause mortality at 5 years
Time frame: 5 years
Rate of cardiovascular mortality
Rate of cardiovascular mortality at 5 years
Time frame: 5 years
Rate of myocardial infarction
Rate of myocardial infarction at 5 years
Time frame: 5 years
Rate of repeat revascularization
Rate of repeat revascularization at 5 years
Time frame: 5 years
Rate of stroke
Rate of stroke at 5 years
Time frame: 5 years
Rate of new or worsening heart failure
Rate of new or worsening heart failure at 5 years
Time frame: 5 years
Rate of new or worsening heart failure
Rate of new or worsening heart failure at 1 year
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2009 (actual). Primary completion is estimated for Jan 2024, 180 months after the start.
Of 634 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 180 months is above that.
Counting every sponsor, half of 759 studies reached it within 40 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Centre of Serbia